Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

14.44USD
9:00pm BST
Change (% chg)

$-0.33 (-2.23%)
Prev Close
$14.77
Open
$14.70
Day's High
$14.97
Day's Low
$14.03
Volume
578,416
Avg. Vol
467,984
52-wk High
$49.87
52-wk Low
$11.50

Atwood, Brian 

Mr. Brian G. Atwood is Independent Director of the Company. Until December 2017, he was President and CEO as well as a co-founder of Cell Design Labs, Inc., a biotechnology company focused on developing human cell engineering technology for the treatment of multiple diseases, including cancer. In 1999, he co-founded and currently serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm. Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. Mr. Atwood also serves on the board of the biotechnology company, Atreca, Inc. Mr. Atwood also served on the boards of Five Prime Therapeutics (NASDAQ: FPRX), Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) acquired in 2014, Immune Design (NASDAQ: IMDZ), Veracyte (NASDAQ: VCYT), Helicos Biosciences (NASDAQ: HLCS), Pharmion Corporation (acquired in 2008) and Trius Therapeutics, Inc. (NASDAQ: TSRX) acquired in 2013. Mr. Atwood holds a B.S. in biological sciences from the University of California, Irvine, a M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University. We believe that Mr. Atwood possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the venture capital industry, his years of business and leadership experience and his financial sophistication and expertise.

Basic Compensation

Total Annual Compensation, USD 65,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 299,979
Fiscal Year Total, USD 364,979

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ginger Graham

357,479

Patrick Mahaffy

6,267,460

Gillian Ivers-Read

1,764,020

Daniel Muehl

1,509,580

Paul Gross

--

Ann Bozeman

--
As Of  31 Dec 2018